Chad Heatwole1, Nicholas Johnson2, Rita Bode2, Jeanne Dekdebrun2, Nuran Dilek2, James E Hilbert2, Elizabeth Luebbe2, William Martens2, Michael P McDermott2, Christine Quinn2, Nan Rothrock2, Charles Thornton2, Barbara G Vickrey2, David Victorson2, Richard T Moxley2. 1. From the Departments of Neurology (C.H., J.D., N.D., J.E.H., E.L., W.M., M.P.M., C.T., R.T.M.) and Biostatistics and Computational Biology (M.P.M.), and James P. Wilmot Cancer Institute (C.Q.), University of Rochester Medical Center, Rochester, NY; University of Utah (N.J.), Salt Lake City; Northwestern University Feinberg School of Medicine (R.B., N.R., D.V.), Chicago, IL; David Geffen School of Medicine (B.G.V.), UCLA Medical Center, Los Angeles; and Greater Los Angeles VA HealthCare System (B.G.V.), CA. Chad_Heatwole@urmc.rochester.edu. 2. From the Departments of Neurology (C.H., J.D., N.D., J.E.H., E.L., W.M., M.P.M., C.T., R.T.M.) and Biostatistics and Computational Biology (M.P.M.), and James P. Wilmot Cancer Institute (C.Q.), University of Rochester Medical Center, Rochester, NY; University of Utah (N.J.), Salt Lake City; Northwestern University Feinberg School of Medicine (R.B., N.R., D.V.), Chicago, IL; David Geffen School of Medicine (B.G.V.), UCLA Medical Center, Los Angeles; and Greater Los Angeles VA HealthCare System (B.G.V.), CA.
Abstract
OBJECTIVE: To determine the frequency and relative importance of the most life-affecting symptoms in myotonic dystrophy type 2 (DM2) and to identify the factors that have the strongest association with these symptoms. METHODS: We conducted a cross-sectional study of adult patients with DM2 from a National Registry of DM2 Patients to assess the prevalence and relative importance of 310 symptoms and 21 symptomatic themes. Participant responses were compared by age categories, sex, educational attainment, employment status, and duration of symptoms. RESULTS: The symptomatic themes with the highest prevalence in DM2 were the inability to do activities (94.4%), limitations with mobility or walking (89.2%), hip, thigh, or knee weakness (89.2%), fatigue (89.2%), and myotonia (82.6%). Participants identified the inability to do activities and fatigue as the symptomatic themes that have the greatest overall effect on their lives. Unemployment, a longer duration of symptoms, and less education were associated with a higher average prevalence of all symptomatic themes (p < 0.01). Unemployment, a longer duration of symptoms, sex, and increased age were associated with a higher average effect of all symptomatic themes among patients with DM2 (p < 0.01). CONCLUSIONS: The lives of patients with DM2 are affected by a variety of symptoms. These symptoms have different levels of significance and prevalence in this population and vary across DM2 subgroups in different demographic categories.
OBJECTIVE: To determine the frequency and relative importance of the most life-affecting symptoms in myotonic dystrophy type 2 (DM2) and to identify the factors that have the strongest association with these symptoms. METHODS: We conducted a cross-sectional study of adult patients with DM2 from a National Registry of DM2Patients to assess the prevalence and relative importance of 310 symptoms and 21 symptomatic themes. Participant responses were compared by age categories, sex, educational attainment, employment status, and duration of symptoms. RESULTS: The symptomatic themes with the highest prevalence in DM2 were the inability to do activities (94.4%), limitations with mobility or walking (89.2%), hip, thigh, or knee weakness (89.2%), fatigue (89.2%), and myotonia (82.6%). Participants identified the inability to do activities and fatigue as the symptomatic themes that have the greatest overall effect on their lives. Unemployment, a longer duration of symptoms, and less education were associated with a higher average prevalence of all symptomatic themes (p < 0.01). Unemployment, a longer duration of symptoms, sex, and increased age were associated with a higher average effect of all symptomatic themes among patients with DM2 (p < 0.01). CONCLUSIONS: The lives of patients with DM2 are affected by a variety of symptoms. These symptoms have different levels of significance and prevalence in this population and vary across DM2 subgroups in different demographic categories.
Authors: C L Liquori; K Ricker; M L Moseley; J F Jacobsen; W Kress; S L Naylor; J W Day; L P Ranum Journal: Science Date: 2001-08-03 Impact factor: 47.728
Authors: Alide A Tieleman; Hans Knoop; Anne-Els van de Logt; Gijs Bleijenberg; Baziel G M van Engelen; Sebastiaan Overeem Journal: J Neurol Neurosurg Psychiatry Date: 2010-09 Impact factor: 10.154
Authors: J W Day; K Ricker; J F Jacobsen; L J Rasmussen; K A Dick; W Kress; C Schneider; M C Koch; G J Beilman; A R Harrison; J C Dalton; L P W Ranum Journal: Neurology Date: 2003-02-25 Impact factor: 9.910
Authors: Mark P Jensen; Amy J Hoffman; Brenda L Stoelb; Richard T Abresch; Gregory T Carter; Craig M McDonald Journal: Arch Phys Med Rehabil Date: 2008-02 Impact factor: 3.966
Authors: Jordi Miró; Katherine A Raichle; Gregory T Carter; Sarah A O'Brien; Richard T Abresch; Craig M McDonald; Mark P Jensen Journal: Am J Hosp Palliat Care Date: 2009-05-04 Impact factor: 2.500
Authors: Martina Minnerop; Bernd Weber; Jan-Christoph Schoene-Bake; Sandra Roeske; Sandra Mirbach; Christian Anspach; Christiane Schneider-Gold; Regina C Betz; Christoph Helmstaedter; Marc Tittgemeyer; Thomas Klockgether; Cornelia Kornblum Journal: Brain Date: 2011-11-29 Impact factor: 13.501
Authors: Johanna Hamel; Nicholas Johnson; Rabi Tawil; William B Martens; Nuran Dilek; Michael P McDermott; Chad Heatwole Journal: Neurology Date: 2019-08-13 Impact factor: 9.910
Authors: Robert D Guber; Angela D Kokkinis; Alice B Schindler; Roxanna M Bendixen; Chad R Heatwole; Kenneth H Fischbeck; Christopher Grunseich Journal: Muscle Nerve Date: 2017-09-25 Impact factor: 3.217
Authors: Phillip Mongiovi; Nuran Dilek; Connie Garland; Michael Hunter; John T Kissel; Elizabeth Luebbe; Michael P McDermott; Nicholas Johnson; Chad Heatwole Journal: Neurology Date: 2018-08-24 Impact factor: 11.800
Authors: Brittney A Otero; Kiril Poukalov; Ryan P Hildebrandt; Charles A Thornton; Kenji Jinnai; Harutoshi Fujimura; Takashi Kimura; Katharine A Hagerman; Jacinda B Sampson; John W Day; Eric T Wang Journal: Cell Rep Date: 2021-01-19 Impact factor: 9.995